# US 2019/0376957 A1 · Solid phase conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376957 A1
- Document ID: US20190376957A1
- Status: Published application
- Kind: A1
- Application number: 16/331,842
- Filed: 2017-09-08
- Published: 2019-12-12
- Earliest claimed: 2016-09-08
- Assignees: BBI Solutions OEM Limited
- Applicants: BBI Solutions OEM Limited
- Inventors: Ffion Walters; Morgan West
- Web page: https://patentgrep.com/patent/US20190376957A1

## CPC

- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- C12Q 1/6834: Enzymatic or biochemical coupling of nucleic acids to a solid phase
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a solid phase biomolecule conjugate for use in a detection assay, comprising on the surface thereof a population of oligonucleotides, and a specific binding partner. The oligonucleotides serve to block the sites which are not bound by a specific binding partner and increase sensitivity for a target molecule to be detected in a sample.

## Claims

### Claim 1

A solid phase biomolecule conjugate for specific binding to a target molecule, the conjugate comprising a solid phase comprising a surface, wherein the surface has bound thereto i) a binding partner specific for the target molecule, and ii) a population of oligonucleotides which do not bind to the target molecule, wherein each oligonucleotide is between 2 to 200 nucleotides in length.

### Claim 2 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein the population of oligonucleotides are provided on the surface of the solid phase over substantially the entire surface which is not bound by the binding partner.

### Claim 3 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein the oligonucleotides of the population do not bind to or any other molecule present in the sample, either in a specific or non-specific manner, and preferably do not bind to the specific binding partner.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein the oligonucleotides of the population each independently comprises or consists of a sequence selected from a poly(A), poly(T), poly(C) or poly(G) sequence.

### Claim 7 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein each or a oligonucleotide of the population is a 10 base poly T sequence with a thiol modification or is a poly T sequence/poly A sequence duplex.

### Claim 8 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein the oligonucleotides of the population are each independently a double stranded molecule; or comprise a blocking group such as a chemical species.

### Claim 9 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein the solid phase is a chip, a particle, a well, a cuvette, a column, a membrane, an array, quantum dots or a bead.

### Claim at position 9

10-12. (canceled)

### Claim 13 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein the surface comprises gold or the particle is a gold particle.

### Claim 14 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein a specific binding partner is either a biological molecule selected from a nucleic acid molecule, a polypeptide comprising an antibody, an antibody fragment or other polypeptide, a hapten or a polysaccharide; or non-biological selected from a small molecule and a drug.

### Claim at position 12

15-21. (canceled)

### Claim 22 (depends on 1)

A solid phase biomolecule conjugate according to claim 1, for detecting a target molecule, wherein the target molecule is either a biological molecule selected from a nucleic acid molecule, a polypeptide, a hapten, or a polysaccharide, a biomolecule or combinations thereof such as nucleic acid-protein complexes, microorganisms, and viruses; or a non-biological molecule selected from a small molecule or drug, or a metal ion.

### Claim at position 14

23-28. (canceled)

### Claim 29 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein the oligonucleotides of the population are each independently 2 nucleotides to 200 nucleotides in length.

### Claim 30 (depends on 1)

A solid phase biomolecule conjugate according to claim 1 wherein a blocking agent is not present on the surface of the solid-phase biomolecule conjugate.

### Claim at position 17

31-32. (canceled)

### Claim 33

A method of detecting a target molecule, the method comprising
a) providing a solid-phase biomolecule conjugate, wherein the conjugate comprises a solid phase having a surface, wherein the surface has attached thereto i) a specific binding partner for the target molecule, and ii) a population of oligonucleotides which do not bind the target molecule, and wherein each oligonucleotide is between 2 to 200 nucleotides in length;
b) contacting the solid-phase biomolecule conjugate with a sample suspected of containing the target molecule;
c) incubating the sample and the conjugate for sufficient time to allow specific binding of the conjugate to any target molecule present in the sample; and
d) detecting a change which occurs upon binding of any target molecule to the conjugate.

### Claim 34 (depends on 33)

A method according to claim 33 wherein the oligonucleotides of the population each independently comprise 2 nucleotides to 200 nucleotides in length.

### Claim 35

(canceled)

### Claim 36 (depends on 1)

A method for making a conjugate as defined in claim 1, wherein the method comprises i) providing a solid phase of the conjugate comprising a surface comprising gold; ii) attaching a specific binding partner for a target molecule to the surface, wherein the binding partner is either a biological molecule selected from a nucleic acid molecule, a polypeptide, a hapten, or a polysaccharide, or a non-biological selected from a small molecule and a drug; and iii) attaching a population of oligonucleotides to the surface which do not bind to the target molecule, and wherein each oligonucleotide is between 2 to 200 nucleotides in length.

### Claim 37

(canceled)

### Claim 38 (depends on 36)

A method according to claim 36 wherein each or a oligonucleotide is a 10 base poly T sequence with a thiol modification.

### Claim 39

(canceled)

### Claim 40 (depends on 36)

A method according to claim 36, wherein the step of attaching in step ii), step iii), or both steps ii) and iii) is independently selected from conjugation chemistries comprising 1 Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), sulfo-NHS coupling, hydrophobic binding or thioether chemistry, or is via a functional group associated with the solid surface or the oligonucleotide or specific binding partner, respectively.

### Claim 41 (depends on 36)

A method according to claim 36 wherein step ii) comprises attaching a specific binding partner indirectly to the solid phase via a larger carrier molecule or protein or attaching a specific binding partner to the solid phase surface by passive adsorption.

### Claim 42

(canceled)

### Claim at position 28

43-46. (canceled)

### Claim 47 (depends on 36)

A method according to claim 36 wherein step ii) comprises providing suitable conditions to allow a covalent or non-covalent bond to form between a reactive group provided on a oligonucleotide and a gold surface of the conjugate.

### Claim 48 (depends on 36)

A method according to claim 36 wherein the bond is covalent, and step iii) comprises incubating the solid phase with the oligonucleotide population in the presence of salt and non-ionic surfactant.

### Claim at position 31

49-51. (canceled)
